Long-term efficacy and safety of azathioprine in ulcerative colitis

Journal of Crohn's and Colitis

Volumn 9, Issue 2, 2015, Pages 191-197

  Sood, Ruchit ^a,b   Ansari, Saqib ^a   Clark, Tanya ^a   Hamlin, P John ^a   Ford, Alexander C ^a,b  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Azathioprine; Colectomy; Efficacy; Immunomodulator; Thiopurine; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; GLUCOCORTICOID; MESALAZINE; IMMUNOSUPPRESSIVE AGENT;

ACUTE PANCREATITIS; ADULT; ADVERSE OUTCOME; ARTHRALGIA; ARTICLE; BIOLOGICAL THERAPY; BONE MARROW TOXICITY; BRAIN TUMOR; BREAST CANCER; COHORT ANALYSIS; COLON RESECTION; COLORECTAL CANCER; CONTROLLED STUDY; DERMATITIS; DISEASE EXACERBATION; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HOSPITAL ADMISSION; HUMAN; LIVER TOXICITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; NEUTROPENIA; NON MELANOMA SKIN CANCER; ONSET AGE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEPSIS; SEX DIFFERENCE; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS; VOMITING; CLINICAL TRIAL; COLITIS, ULCERATIVE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; REMISSION; TIME;

ADULT; AZATHIOPRINE; COLITIS, ULCERATIVE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; PROSPECTIVE STUDIES; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84953860948     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1093/ecco-jcc/jju010     Document Type: Article

References (30)

1. Dignass A, Eliakim R, Magro F, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis 2012;6:965-90
2. Ford AC, Achkar JP, Khan KJ, et al. Efficacy of 5-aminosalicylates in ulcerative colitis: systematic review and meta-analysis. Am J Gastroenterol 2011;106:601-16
3. Ford AC, Bernstein CN, Khan KJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011;106:590-9; quiz 600
4. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis 2012;6:991-1030
5. Sandborn W, Sutherland L, Pearson D, May G, Modigliani R, Prantera C. Azathioprine or 6-mercaptopurine for inducing remission of Crohn's disease. Cochrane Database Syst Rev 2000:Cd000545
6. Pearson DC, May GR, Fick G, Sutherland LR. Azathioprine for maintaining remission of Crohn's disease. Cochrane Database Syst Rev 2000:Cd000067
7. Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011;60:571-607
8. Lichtenstein GR, Abreu MT, Cohen R, Tremaine W. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006;130:940-87
9. Khan KJ, Dubinsky MC, Ford AC, Ullman TA, Talley NJ, Moayyedi P. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011;106:630-42
10. Jewell DP, Truelove SC. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J 1974;4:627-30
11. Sood A, Midha V, Sood N, Kaushal V. Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial. Indian J Gastroenterol 2000;19:14-6
12. Sood A, Kaushal V, Midha V, Bhatia KL, Sood N, Malhotra V. The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis. J Gastroenterol 2002;37:270-4
13. Reinisch W, Van Assche G, Befrits R, et al. Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensus. J Crohns Colitis 2012;6:248-58
14. Reinisch W, Sandborn WJ, Hommes DW, et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 2011;60:780-7
15. Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology 2012;142:257-65.e1-3
16. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19 Suppl A:5a-36a
17. Oren R, Arber N, Odes S, et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996;110:1416-21
18. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625-9
19. Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002;50:485-9
20. Ardizzone S, Molteni P, Imbesi V, Bollani S, Bianchi Porro G. Azathioprine in steroid-resistant and steroid-dependent ulcerative colitis. J Clin Gastroenterol 1997;25:330-3
21. Falasco G, Zinicola R, Forbes A. Review article: Immunosuppressants in distal ulcerative colitis. Aliment Pharmacol Ther 2002;16:181-7
22. Hibi T, Naganuma M, Kitahora T, Kinjyo F, Shimoyama T. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. J Gastroenterol 2003;38:740-6
23. Christodoulou D, Katsanos K, Baltayannis G, Tzabouras N, Tsianos EV. A report on efficacy and safety of azathioprine in a group of inflammatory bowel disease patients in northwest Greece. Hepatogastroenterology 2003;50:1021-4
24. Gisbert JP, Linares PM, McNicholl AG, Mate J, Gomollon F. Meta-analysis: The efficacy of azathioprine and mercaptopurine in ulcerative colitis. Aliment Pharmacol Ther 2009;30:126-37
25. Holtmann MH, Krummenauer F, Claas C, et al. Long-term effectiveness of azathioprine in IBD beyond 4 years: a European multicenter study in 1176 patients. Dig Dis Sci 2006;51:1516-24
26. Cassinotti A, Actis GC, Duca P, et al. Maintenance treatment with azathioprine in ulcerative colitis: outcome and predictive factors after drug withdrawal. Am J Gastroenterol 2009;104:2760-7
27. Chebli LA, Chaves LD, Pimentel FF, et al. Azathioprine maintains longterm steroid-free remission through 3 years in patients with steroiddependent ulcerative colitis. Inflamm Bowel Dis 2010;16:613-9
28. Gisbert JP, Nino P, Cara C, Rodrigo L. Comparative effectiveness of azathioprine in Crohn's disease and ulcerative colitis: prospective, long-term, follow-up study of 394 patients. Aliment Pharmacol Ther 2008;28:228-38
29. Actis GC, Fadda M, Pellicano R, David E, Rizzetto M, Sapino A. The 17-year single-center experience with the use of azathioprine to maintain remission in ulcerative colitis. Biomed Pharmacother 2009;63:362-5
30. Chouchana L, Narjoz C, Beaune P, Loriot MA, Roblin X. Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease. Aliment Pharmacol Ther 2012;35:15-36